Loading paragraph...
Today's Biggest Stock Losers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| NOMA | Nomadar | $9.60 | -$11.40 | -54.29% | 147.8K | - | $2.00$57.70 |
| QURE | uniQure | $33.01 | -$34.68 | -51.23% | 18.7M | $4.2B | $5.35$71.50 |
| ALVO | Alvotech | $5.05 | -$2.60 | -33.99% | 2.1M | $2.3B | $5.01$13.70 |
| NCEL | NewcelX | $5.18 | -$2.11 | -28.94% | 252.8K | $31.0M | $4.20$47.40 |
| NVA | Nova Minerals | $7.01 | -$1.92 | -21.50% | 1.4M | $61.1M | $1.40$16.28 |
| CLPT | ClearPoint Neuro | $18.24 | -$4.98 | -21.44% | 2.6M | $660.1M | $9.76$30.10 |
| SOLT | Volatility Shares Trust - 2x Solana ETF | $13.58 | -$3.69 | -21.35% | 13.8M | - | $7.74$35.30 |
| RGTX | Tidal Trust II - Defiance Daily Target 2x Long Rgti ETF | $205.55 | -$55.08 | -21.14% | 566.5K | - | $14.93$501.80 |
| CMBM | Cambium Networks | $2.36 | -$0.63 | -21.07% | 4.9M | $84.4M | $0.23$6.80 |
| SOC | Sable Offshore | $8.30 | -$2.16 | -20.65% | 7.3M | $1.0B | $7.73$35.00 |
Related Articles
Featured Article
Up 152% in December, Is uniQure a Good Stock to Buy Now and Hold Through 2025?
Cory Renauer|Dec 15, 2024
This Under-the-Radar Growth Stock Could Soar by 277%, According to Wall Street
George Budwell|Aug 16, 2023
This small-cap biotech might be a hidden gem.
Better Recovery-Story Buy: Emergent BioSolutions or Invitae?
Adria Cimino|Jun 26, 2023
Both of these stocks have plummeted more than 50% over the past year.
Is Emergent BioSolutions Stock a Buy Now?
Alex Carchidi|Jun 9, 2023
The deluge of bad news seems to be over, and a recovery could be in the works.
Down 75%, Can Emergent BioSolutions Turn Things Around?
David Jagielski|Jun 7, 2023
Has the stock finally bottomed out?
3 Monkeypox Stocks That Soared Last Week
Cory Renauer|May 23, 2022
Fear of another viral outbreak is generating a lot of buzz around these three biotech stocks.
Late-Stage Clinical Study Readouts Biotech Investors Should Watch
Keith Speights and Brian Orelli, PhD|Jul 11, 2021
Several drugmakers have important clinical trial updates on the way.
Can Emergent BioSolutions Recover From Its Recent Blunders?
Keith Speights and Brian Orelli, PhD|Jul 3, 2021
Yes, but it probably won't be an easy path.
The Biggest Loser With Johnson & Johnson's COVID Vaccine Manufacturing Woes
Keith Speights and Brian Orelli, PhD|May 6, 2021
It's obvious.
Is Emergent BioSolutions Still a Buy After Its Coronavirus Vaccine Flub?
Alex Carchidi|May 4, 2021
Shareholders beware: The hits just won't stop coming.
